Amgen Inc. Drug Patent Portfolio
Amgen Inc. owns 2 purple book drugs protected by 48 US patents Given below is the list of Amgen Inc.'s drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11744950 | Controlled dispense syringe | 21 Nov, 2039 | Active |
| US11098079 | Charged depth filtration of antigen-binding proteins | 21 Jul, 2037 | Active |
| US11275090 | Quantitation of glycan moiety in recombinant glycoproteins | 02 Jul, 2037 | Active |
| US10167492 | Process for manipulating the level of glycan content of a glycoprotein | 01 Dec, 2035 | Active |
| US10822630 | Process for manipulating the level of glycan content of a glycoprotein | 01 Dec, 2035 | Active |
| US11786866 | Process control systems and methods for use with filters and filtration processes | 21 Oct, 2035 | Active |
| US10583397 | Process control systems and methods for use with filters and filtration processes | 28 Jul, 2035 | Active |
| US11384378 | Methods for harvesting mammalian cell cultures | 04 Jun, 2035 | Active |
| US11427848 | Methods for harvesting mammalian cell cultures | 04 Jun, 2035 | Active |
| US11077404 | Process control systems and methods for use with filters and filtration processes | 13 May, 2035 | Active |
| US11130980 | Use of monensin to regulate glycosylation of recombinant proteins | 05 Apr, 2035 | Active |
| US10106829 | Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins | 11 Dec, 2034 | Active |
| US10227627 | Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins | 11 Dec, 2034 | Active |
| US10655156 | Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins | 11 Dec, 2034 | Active |
| US10907186 | Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins | 11 Dec, 2034 | Active |
| US10513723 | Decreasing ornithine production to decrease high mannose glycoform content of recombinant proteins | 09 Dec, 2034 | Active |
| US11254963 | Increasing ornithine accumulation to increase high mannose glycoform content of recombinant proteins | 09 Dec, 2034 | Active |
| US11299760 | Use of monensin to regulate glycosylation of recombinant proteins | 30 Oct, 2034 | Active |
| US10421987 | Methods for increasing mannose content of recombinant proteins | 29 May, 2034 | Active |
| US10894972 | Methods for increasing mannose content of recombinant proteins | 29 May, 2034 | Active |
| US11434514 | Methods for increasing mannose content of recombinant proteins | 29 May, 2034 | Active |
| US11946085 | Methods for increasing mannose content of recombinant proteins | 29 May, 2034 | Active |
| US9481901 | Methods for increasing mannose content of recombinant proteins | 29 May, 2034 | Active |
| US11319568 | Methods for increasing mannose content of recombinant proteins | 10 Mar, 2034 | Active |
| US11459595 | Methods for increasing mannose content of recombinant proteins | 10 Mar, 2034 | Active |
| US11952605 | Methods for increasing mannose content of recombinant proteins | 10 Mar, 2034 | Active |
| US9328134 | Carbohydrate phosphonate derivatives as modulators of glycosylation | 20 Feb, 2034 | Active |
| US11486883 | Method for using light scattering in real time to directly monitor and control impurity removal in purification processes | 26 Mar, 2033 | Active |
| US11292829 | Mammalian cell culture | 29 Jun, 2032 | Active |
| US11634476 | Mammalian cell culture | 29 Jun, 2032 | Active |
| US11685772 | Mammalian cell culture | 29 Jun, 2032 | Active |
| US9133493 | Method for culturing mammalian cells to improve recombinant protein production | 20 Apr, 2032 | Active |
| US9388447 | Method for culturing mammalian cells to improve recombinant protein production | 20 Apr, 2032 | Active |
| US9012178 | Dipeptides to enhance yield and viability from cell cultures | 05 Aug, 2031 | Active |
| US9320816 | Methods of treating cell culture media for use in a bioreactor | 14 Nov, 2030 | Active |
| US9856287 | Refolding proteins using a chemically controlled redox state | 21 Jun, 2030 | Active |
| US8053236 | Feed media | 19 Jan, 2030 | Active |
| US9228168 | Feed media | 19 Jan, 2030 | Active |
| US9359435 | Methods for modulating mannose content of recombinant proteins | 22 May, 2027 | Active |
| US7662930 | Polishing steps used in multi-step protein purification processes | 24 Apr, 2027 | Active |
| US7888101 | Host cells comprising alpha 1,2 mannosidase and culture methods thereof | 06 Apr, 2027 | Active |
| US7928205 | Methods for refolding of recombinant antibodies | 12 Feb, 2027 | Active |
| US8247210 | Host cells comprising alpha 1,2 mannosidase and culture methods thereof | 06 Dec, 2026 | Active |
| US8460896 | Host cells and culture methods | 06 Dec, 2026 | Active |
| US8680248 | Host cells comprising alpha 1,2 mannosidase and culture methods thereof | 06 Dec, 2026 | Active |
| US7427659 | Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction | 15 Mar, 2025 | Active |
| US7364736 | Antibodies to OPGL | 19 Feb, 2025 | Active |
| US8058418 | Polynucleotides encoding heavy and light chains of antibodies to OPGL | 30 Nov, 2023 | Active |
Amgen Inc.'s Family Patents
Amgen Inc. Drug List
Given below is the complete list of Amgen Inc.'s drugs and the patents protecting them.
1. Neulasta
Neulasta is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9856287 | Refolding proteins using a chemically controlled redox state |
21 Jun, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Neulasta's drug page
2. Prolia And Xgeva
Prolia And Xgeva is protected by 47 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11744950 | Controlled dispense syringe |
21 Nov, 2039
(15 years from now)
| Active |
| US11098079 | Charged depth filtration of antigen-binding proteins |
21 Jul, 2037
(12 years from now)
| Active |
| US11275090 | Quantitation of glycan moiety in recombinant glycoproteins |
02 Jul, 2037
(12 years from now)
| Active |
| US10167492 | Process for manipulating the level of glycan content of a glycoprotein |
01 Dec, 2035
(11 years from now)
| Active |
| US10822630 | Process for manipulating the level of glycan content of a glycoprotein |
01 Dec, 2035
(11 years from now)
| Active |
| US11786866 | Process control systems and methods for use with filters and filtration processes |
21 Oct, 2035
(10 years from now)
| Active |
| US10583397 | Process control systems and methods for use with filters and filtration processes |
28 Jul, 2035
(10 years from now)
| Active |
| US11384378 | Methods for harvesting mammalian cell cultures |
04 Jun, 2035
(10 years from now)
| Active |
| US11427848 | Methods for harvesting mammalian cell cultures |
04 Jun, 2035
(10 years from now)
| Active |
| US11077404 | Process control systems and methods for use with filters and filtration processes |
13 May, 2035
(10 years from now)
| Active |
| US11130980 | Use of monensin to regulate glycosylation of recombinant proteins |
05 Apr, 2035
(10 years from now)
| Active |
| US10106829 | Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins |
11 Dec, 2034
(10 years from now)
| Active |
| US10227627 | Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins |
11 Dec, 2034
(10 years from now)
| Active |
| US10655156 | Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins |
11 Dec, 2034
(10 years from now)
| Active |
| US10907186 | Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins |
11 Dec, 2034
(10 years from now)
| Active |
| US10513723 | Decreasing ornithine production to decrease high mannose glycoform content of recombinant proteins |
09 Dec, 2034
(10 years from now)
| Active |
| US11254963 | Increasing ornithine accumulation to increase high mannose glycoform content of recombinant proteins |
09 Dec, 2034
(10 years from now)
| Active |
| US11299760 | Use of monensin to regulate glycosylation of recombinant proteins |
30 Oct, 2034
(9 years from now)
| Active |
| US10421987 | Methods for increasing mannose content of recombinant proteins |
29 May, 2034
(9 years from now)
| Active |
| US10894972 | Methods for increasing mannose content of recombinant proteins |
29 May, 2034
(9 years from now)
| Active |
| US11434514 | Methods for increasing mannose content of recombinant proteins |
29 May, 2034
(9 years from now)
| Active |
| US11946085 | Methods for increasing mannose content of recombinant proteins |
29 May, 2034
(9 years from now)
| Active |
| US9481901 | Methods for increasing mannose content of recombinant proteins |
29 May, 2034
(9 years from now)
| Active |
| US11319568 | Methods for increasing mannose content of recombinant proteins |
10 Mar, 2034
(9 years from now)
| Active |
| US11459595 | Methods for increasing mannose content of recombinant proteins |
10 Mar, 2034
(9 years from now)
| Active |
| US11952605 | Methods for increasing mannose content of recombinant proteins |
10 Mar, 2034
(9 years from now)
| Active |
| US9328134 | Carbohydrate phosphonate derivatives as modulators of glycosylation |
20 Feb, 2034
(9 years from now)
| Active |
| US11486883 | Method for using light scattering in real time to directly monitor and control impurity removal in purification processes |
26 Mar, 2033
(8 years from now)
| Active |
| US11292829 | Mammalian cell culture |
29 Jun, 2032
(7 years from now)
| Active |
| US11634476 | Mammalian cell culture |
29 Jun, 2032
(7 years from now)
| Active |
| US11685772 | Mammalian cell culture |
29 Jun, 2032
(7 years from now)
| Active |
| US9133493 | Method for culturing mammalian cells to improve recombinant protein production |
20 Apr, 2032
(7 years from now)
| Active |
| US9388447 | Method for culturing mammalian cells to improve recombinant protein production |
20 Apr, 2032
(7 years from now)
| Active |
| US9012178 | Dipeptides to enhance yield and viability from cell cultures |
05 Aug, 2031
(6 years from now)
| Active |
| US9320816 | Methods of treating cell culture media for use in a bioreactor |
14 Nov, 2030
(5 years from now)
| Active |
| US8053236 | Feed media |
19 Jan, 2030
(5 years from now)
| Active |
| US9228168 | Feed media |
19 Jan, 2030
(5 years from now)
| Active |
| US9359435 | Methods for modulating mannose content of recombinant proteins |
22 May, 2027
(2 years from now)
| Active |
| US7662930 | Polishing steps used in multi-step protein purification processes |
24 Apr, 2027
(2 years from now)
| Active |
| US7888101 | Host cells comprising alpha 1,2 mannosidase and culture methods thereof |
06 Apr, 2027
(2 years from now)
| Active |
| US7928205 | Methods for refolding of recombinant antibodies |
12 Feb, 2027
(2 years from now)
| Active |
| US8247210 | Host cells comprising alpha 1,2 mannosidase and culture methods thereof |
06 Dec, 2026
(2 years from now)
| Active |
| US8460896 | Host cells and culture methods |
06 Dec, 2026
(2 years from now)
| Active |
| US8680248 | Host cells comprising alpha 1,2 mannosidase and culture methods thereof |
06 Dec, 2026
(2 years from now)
| Active |
| US7427659 | Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction |
15 Mar, 2025
(3 months from now)
| Active |
| US7364736 | Antibodies to OPGL |
19 Feb, 2025
(3 months from now)
| Active |
| US8058418 | Polynucleotides encoding heavy and light chains of antibodies to OPGL |
30 Nov, 2023
(11 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prolia And Xgeva's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List